Johnson & Johnson enters its third-quarter report as a company running at two speeds. Its pharmaceutical franchise is pulling hard on the back of Tremfiya and a wave of newer launches. Its MedTech business, meanwhile, lost momentum in cardiovascular devices, the area that had been its growth engine. Last quarter the drug side was strong enough to support a guidance raise. The question now is whether it can keep doing so while Abiomed and electrophysiology work through problems that management described as temporary.

Wall Street is looking for earnings of $2.90 a share on revenue of about $25.37 billion. That would mean sales growth of 5.7% but earnings growth of only 3.6% from a year ago. The Earnings Whisper sits a touch higher at $2.93, which suggests the informal bar is slightly above the published one, though not by enough to signal outsized optimism. Profit growth trailing revenue growth matters here. Management has lifted its target for pre-tax operating margin improvement to roughly 75 basis points this year, helped by tariff recoupment. A quarter where earnings barely outpace flat sequential results would test that promise of operating leverage.

Full-year guidance now calls for earnings of $11.60 to $11.75 a share on revenue of $100.3 billion to $100.9 billion. The EPS range moved up, but the top of the revenue range came down from $101.3 billion. The consensus of $11.58 sits just below the low end of the earnings outlook, which gives J&J room to beat on profit. The revenue consensus of $100.81 billion, by contrast, sits near the top of a narrower sales range. That split matters. The setup favors an earnings beat driven by margins and below-the-line items such as a lower tax rate and lighter interest expense, while leaving little cushion on the top line.

The operating story starts with Innovative Medicine. Excluding Stelara, which is losing sales to competition, the segment grew about 14% last quarter. Tremfiya growth sped up to 71% and topped $2 billion in a quarter for the first time. Confirmation would look like continued strength in Tremfiya's share of new inflammatory bowel disease patients, broader uptake of Icotide after its consumer advertising push, and further gains for Inlexo beyond the one in three eligible patients it reached last quarter. Oncology deserves attention too. Tecvali's growth nearly doubled to 56% after its combination approval with Darzalex Faspro, and another quarter at that pace would show the approval is working as a lasting catalyst rather than a single bump. The Firefly Bio deal, expected to close this quarter, should also add pipeline detail.

MedTech is where the narrative could crack. Abiomed swung to a 2% decline after a neutral UK trial in high-risk heart procedures made physicians more selective, and management now expects only modest growth until new data arrive in 2027. Electrophysiology slowed to about 3% growth, weighed down by China inventory. If electrophysiology rebounds as that inventory clears, it would support the view that the slowdown is temporary. Another soft quarter would suggest share or pricing pressure in a market J&J once dominated. Any update on the expected second-half approval of the Otava surgical robot will also shape the longer-term device story.

The market has been lukewarm. Shares are up 2.4% since the last report, roughly in line with the S&P 500. Bullish sentiment has dipped slightly from the prior quarter. At $256, the stock trades comfortably above its 200-day average but well off its post-earnings high of $281, so it is consolidating rather than pressing a breakout. The central issue is whether drug launches can keep growing fast enough to absorb device weakness without another trim to the sales outlook. If they can, the case that J&J is headed for double-digit growth later this decade stays intact.